1887

Nordic Economic Policy Review

Challenges in health care financing and provision

image of Nordic Economic Policy Review

The Nordic Economic Policy Review is published by the Nordic Council of Ministers and addresses policy issues in a way that is useful for in-formed non-specialists as well as for professional economists. All articles are commissioned from leading professional economists and are subject to peer review prior to publication. The review appears twice a year. Content: Challenges in health care financing and provision - Tor Iversen and Sverre A.C. Kittelsen Ageing populations: More care or just later care? - Terkel Christiansen, Jørgen Lauridsen and Mickael Bech Comment by Anna Lilja Gunnarsdottir Lifestyle, health and costs – what does available evidence suggest? - Kristian Bolin Comment by Tinna Laufey Ásgeirsdóttir The economics of long-term care: A survey - Helmuth Cremer, Pierre Pestieau and Gregory Ponthiere Comment by Þórólfur Matthíasson The role of primary health care in controlling the cost of specialist health care - Stephen Beales and Peter C. Smith Comment by Helgi Tómasson Payments in support of effective primary care for chronic conditions - Randall P. Ellis and Arlene S. Ash Comment by Jørgen T. Lauridsen An economic assessment of price rationing versus non-price rationing of health care - Luigi Siciliani Comment by Mickael Bech Should pharmaceutical costs be curbed? - Kurt R. Brekke, Dag Morten Dalen and Steinar Strøm Comment by Helgi Tómasson Productivity differences in Nordic hospitals: Can we learn from Finland? - Clas Rehnberg and Unto Häkkinen Comment by Thorvaldur Gylfason

English

.

Should pharmaceutical costs be curbed?

Pharmaceuticals account for almost a fifth of total health spending in OECD-countries. Both pharmaceutical innovations and the aging of the population explain the increasing importance of pharmaceuticals in health care. Due to the importance of patent protection and insurance coverage, pharmaceutical markets are subjected to economic regulation – both on the supply-side and the demand-side. In this paper, we briefly review the Nordic pharmaceutical market, before explaining the main regulatory policy measures taken by governments in these countries. Empirical research has been undertaken to investigate regulation and competition, and we provide a review of some of the findings.

English

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error